Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2020 07:10 ET | Source: Kitov Pharma Ltd.

Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
September 04, 2020 08:00 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219

Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries TEL AVIV, Israel, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”)...
August 12, 2020 16:55 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Announces ADS Ratio Change

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
August 11, 2020 07:15 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results

TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
July 09, 2020 07:30 ET | Source: Kitov Pharma Ltd.

Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer ...
July 08, 2020 07:30 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody

Patent coverage for CM24 now extends to the U.S. and the EU TEL AVIV, Israel, July 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company...
July 02, 2020 08:34 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Issues CEO Shareholder Letter Providing Business Update

• Emerging oncology pipeline continues to advance• Strong balance sheet with over $60M in cash TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE:...
June 25, 2020 16:30 ET | Source: Kitov Pharma Ltd.

Kitov Closes $35.0 Million Registered Direct Offering

TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
June 23, 2020 13:20 ET | Source: Kitov Pharma Ltd.

Kitov Announces $35.0 Million Registered Direct Offering

TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
May 22, 2020 07:00 ET | Source: Kitov Pharma Ltd.

Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients

Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase...